Modulating dynorphin activity by a KRA putatively offers a means for restoring motivation and ability to experience pleasure in depression, as reflected previously by the mechanistic results of the FAST-MAS trial [24, 25] and herein, especially by improvement in MADRS anhedonia factor subscale scores. This evidence concerns the gene PDYN and depressive symptom measurement.